Objective To update the evidence on efficacy and safety of biological disease-modifying
antirheumatic drugs (bDMARDs) in patients with axial spondyloarthritis (axSpA) to inform the …

Axial spondyloarthritides (axSpA) are a group of systemic autoimmune diseases,
characterised by an inflammatory involvement of the axial skeleton, which, in the earlier …

Objective To examine the impact of novel biologic disease-modifying antirheumatic drugs
(bDMARDs) with tumor necrosis factor (TNF) inhibitors or Interleukin-17A (IL-17A) antibody …

Objective We examined the relationships of work productivity and activity impairment with
key patient‐reported outcomes (PROs) assessing pain, disease activity, and health‐related …

Introduction Ankylosing spondylitis (AS) is a chronic condition that requires lifelong
treatment and results in a serious disease burden. Health state utility values (HSUVs) are a …

Methods The phase 3, double-blind, GO-ALIVE study randomized patients to IV golimumab
2 mg/kg at weeks 0 and 4 and then every 8 weeks through week 52, or placebo at weeks 0 …

Introduction We studied the effect of intravenous (IV)-golimumab on fatigue and the
association of fatigue improvement with clinical response post hoc in adults with active …

Долгосрочное влияние нетакимаба на качество жизни, боль в спине и
работоспособность пациентов с анкилозирующим спондилитом: результаты …

Introduction/objectives To evaluate changes in health-related quality of life (HRQoL) and
productivity following treatment with intravenous (IV) golimumab in patients with psoriatic …

With great interest, we read the results of the tight control in spondyloarthritis (TICOSPA)
study 1 in which a tight-control/treat-to-target strategy (T2T) was compared with usual care in …